- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07939529
People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness (PALACE)
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35222
- Alabama (Site ID: 31788)
-
Ta kontakt med:
- Heather Logan
- Telefonnummer: 205-934-6774
- E-post: heatherlogan@uabmc.edu
-
-
California
-
Los Angeles, California, Forente stater, 90035
- University of California, Los Angeles CARE Center (Site ID: 601)
-
Ta kontakt med:
- Aleen Khodabakhshian
- Telefonnummer: 310-557-3798
- E-post: akhodabakhshian@mednet.ucla.edu
-
San Diego, California, Forente stater, 92103
- UCSD Antiviral Research Center (Site ID: 701)
-
Ta kontakt med:
- Dawn Rosenblum
- Telefonnummer: 619-543-8080
- E-post: drosenblum@health.ucsd.edu
-
San Francisco, California, Forente stater, 94110
- University of California, San Francisco (Site ID: 801)
-
Ta kontakt med:
- Jay Dwyer
- Telefonnummer: 415-502-5748
- E-post: jay.dwyer@ucsf.edu
-
Torrance, California, Forente stater, 90502-2052
- Harbor University of California Los Angeles Center (Site ID: 603)
-
Ta kontakt med:
- Mario Guerrero
- Telefonnummer: 323-457-1459
- E-post: mguerrero@lundquist.org
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado Hospital (Site ID: 6101)
-
Ta kontakt med:
- Nicola Haakonsen
- Telefonnummer: 303-724-5931
- E-post: nicola.haakonsen@cuanschutz.edu
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20032
- Whitman-Walker Institute, Inc. (Site ID: 21791)
-
Ta kontakt med:
- Avery Wimpelberg
- Telefonnummer: 202-797-3589
- E-post: awimpelberg@whitman-walker.org
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University (Site ID: 2701)
-
Ta kontakt med:
- Sherryl L Wolfe
- Telefonnummer: 312-695-4997
- E-post: s-wolfe@northwestern.edu
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Johns Hopkins University (Site ID: 201)
-
Ta kontakt med:
- Rebecca L Becker
- Telefonnummer: 410-614-4036
- E-post: rbecke22@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Massachusetts General Hospital (Site ID: 101)
-
Ta kontakt med:
- Amy Sbrolla
- Telefonnummer: 617-726-5598
- E-post: asbrolla@mgh.harvard.edu
-
Boston, Massachusetts, Forente stater, 02115
- Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)
-
Ta kontakt med:
- Hannah Jordan
- Telefonnummer: 617-732-4785
- E-post: hcjordan@bwh.harvard.edu
-
-
New Jersey
-
Newark, New Jersey, Forente stater, 07103
- New Jersey Medical School Clinical Research Center (Site ID: 31786)
-
Ta kontakt med:
- Christie Lyn Costanza
- Telefonnummer: 972-972-9069
- E-post: costancl@njms.rutgers.edu
-
-
New York
-
New York, New York, Forente stater, 10010
- Weill Cornell Chelsea (Site ID: 7804)
-
Ta kontakt med:
- Mauricio Vergara
- Telefonnummer: 212-746-7204
- E-post: mav9177@med.cornell.edu
-
New York, New York, Forente stater, 10010
- Weill Cornell Uptown (Site ID: 7803)
-
Ta kontakt med:
- Keisha Ballentine-Cargill
- Telefonnummer: 212-746-7804
- E-post: keb4006@med.cornell.edu
-
New York, New York, Forente stater, 10032
- Columbia Physicians & Surgeons (P&S) (Site ID: 30329)
-
Ta kontakt med:
- Brett T Gray
- Telefonnummer: 212-305-1570
- E-post: bg2168@cumc.columbia.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599-7215
- Chapel Hill (Site ID: 3201)
-
Ta kontakt med:
- Erin Elizabeth Hoffman
- Telefonnummer: 919-843-0720
- E-post: erin_hoffman@med.unc.edu
-
Greensboro, North Carolina, Forente stater, 27401-1020
- Greensboro (Site ID: 3203)
-
Ta kontakt med:
- Kelly Phillips
- Telefonnummer: 336-832-7297
- E-post: kelly.phillips@conehealth.com
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
Ta kontakt med:
- Michelle Saemann
- Telefonnummer: 513-584-2245
- E-post: saemanmd@ucmail.uc.edu
-
Cleveland, Ohio, Forente stater, 44106
- Case Clinical Research Site (Site ID: 2501)
-
Ta kontakt med:
- Julie Pasternak
- Telefonnummer: 216-844-2738
- E-post: pasternak.julie@clevelandactu.org
-
Columbus, Ohio, Forente stater, 43210
- Ohio State University (Site ID: 2301)
-
Ta kontakt med:
- Lindsay Summers
- Telefonnummer: 614-293-8529
- E-post: lindsay.summers@osumc.edu
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- University of Pittsburgh (Site ID: 1001)
-
Ta kontakt med:
- Stacey Edick
- Telefonnummer: 412-383-1748
- E-post: edicksm2@upmc.edu
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37204
- Vanderbilt Therapeutics (VT) (Site ID: 3652)
-
Ta kontakt med:
- Beverly Woodward
- Telefonnummer: 615-936-8516
- E-post: beverly.o.woodward@vumc.org
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Houston Advancing Research Team (Site ID: 31473)
-
Ta kontakt med:
- Maria Laura Martinez
- Telefonnummer: 713-500-6718
- E-post: maria.l.martinez@uth.tmc.edu
-
-
Washington
-
Seattle, Washington, Forente stater, 98104
- University of Washington Positive Research (Site ID: 1401)
-
Ta kontakt med:
- Allysson Angeldekao
- Telefonnummer: 503-715-7324
- E-post: allysson@uw.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Documented HIV-1 infection
-
Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
-
HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
-
Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
-
At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
-
Adequate laboratory parameters within 60 days prior to study entry:
- Absolute neutrophil count >600/mm3
- Hemoglobin ≥7.0 g/dL
- Platelet count >50,000/μL
- AST and ALT ≤3 × upper limit of normal
- Estimated glomerular filtration rate >15 mL/min/1.73 m²
-
For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry
-
Ability and willingness to provide informed consent
-
Connected to a medical clinic with access to HIV care and antiretroviral therapy
Exclusion Criteria:
- Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
- Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
- Child-Pugh Class C cirrhosis
- No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
- Prior use of lenacapavir
- Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
- Serious medical or psychiatric condition
- Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
- Current pregnancy or breastfeeding
- Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Long-Acting Lenacapavir Plus Long-Acting Cabotegravir
|
Long-acting subcutaneous lenacapavir administered every 24 weeks with oral loading doses at treatment initiation. Long-acting intramuscular cabotegravir administered every 8 weeks following initiation doses. Oral antiretroviral therapy provided as bridge therapy during interruptions or delays in long-acting treatment. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Proportion of participants achieving and maintaining viral suppression (no confirmed virologic failure) while receiving long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 48
|
Baseline through Week 48
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
|
Week 48
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
|
Week 48
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsramme: Week 48
|
Week 48
|
|
|
Proportion of participants with Grade 3 or higher adverse events related to long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir due to adverse events or intolerance
Tidsramme: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure on long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 96
|
Baseline through Week 96
|
|
|
Proportion of participants with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsramme: Week 96
|
Week 96
|
|
|
Proportion of participants with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsramme: Week 96
|
Week 96
|
|
|
Proportion of participants with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsramme: Week 96
|
Week 96
|
|
|
Percentage of on-time long-acting injections
Tidsramme: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Proportion of participants discontinuing long-acting lenacapavir plus cabotegravir
Tidsramme: Baseline through Week 48 and through Week 96
|
Baseline through Week 48 and through Week 96
|
|
|
Plasma trough concentrations of lenacapavir and cabotegravir
Tidsramme: Through Week 48 and through Week 96
|
Through Week 48 and through Week 96
|
|
|
Change in CD4 cell count from baseline
Tidsramme: Week 48 and Week 96
|
Week 48 and Week 96
|
|
|
Participant-reported treatment satisfaction
Tidsramme: Week 48 and Week 96
|
HIV Treatment Satisfaction Questionnaire assesses participant satisfaction with the long-acting treatment. |
Week 48 and Week 96
|
|
Change in quality-of-life scores from baseline
Tidsramme: Week 48 and Week 96
|
Quality of life will be assessed using the Veterans Rand 12-item Health Survey (VR-12). Scores range from 0 to 100, with higher scores indicating better health-related quality of life. |
Week 48 and Week 96
|
|
Change in Patient Health Questionnaire-9 (PHQ-9) scores from baseline
Tidsramme: Week 48 and Week 96
|
Symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. |
Week 48 and Week 96
|
|
Proportion of participants achieving and maintaining viral suppression without confirmed virologic failure among participants not requiring oral bridge therapy
Tidsramme: Baseline through Week 48
|
Baseline through Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <50 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with HIV-1 RNA <200 copies/mL by FDA Snapshot analysis
Tidsramme: Week 48
|
Week 48
|
|
|
Proportion of participants without oral bridge therapy with regimen success, defined as remaining on long-acting lenacapavir plus cabotegravir without confirmed virologic failure
Tidsramme: Week 48
|
Week 48
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- A5431
- 39159 (Annen identifikator: DAIDS-ES ID)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual participant data that underlie results in the publication after deidentification
IPD-delingstidsramme
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
Tilgangskriterier for IPD-deling
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .